News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
600,602 Results
Type
Article (46404)
Company Profile (197)
Press Release (554001)
Section
Business (172256)
Career Advice (2521)
Deals (31810)
Drug Delivery (118)
Drug Development (76045)
Employer Resources (156)
FDA (16158)
Job Trends (13247)
News (304712)
Policy (31786)
Tag
Academia (2353)
Alliances (43226)
Alzheimer's disease (1373)
Approvals (16097)
Artificial intelligence (195)
Bankruptcy (317)
Best Places to Work (9918)
Breast cancer (213)
Cancer (1605)
Cardiovascular disease (129)
Career advice (2107)
CAR-T (118)
Cell therapy (334)
Clinical research (61208)
Collaboration (596)
Compensation (356)
COVID-19 (2621)
C-suite (146)
Data (1453)
Diabetes (210)
Diagnostics (5452)
Earnings (67680)
Employer resources (142)
Events (90306)
Executive appointments (522)
FDA (17002)
Funding (505)
Gene therapy (241)
GLP-1 (732)
Government (3911)
Healthcare (15439)
Infectious disease (2731)
Inflammatory bowel disease (114)
Interviews (460)
IPO (15019)
Job creations (3756)
Job search strategy (1764)
Layoffs (483)
Legal (7682)
Lung cancer (247)
Manufacturing (240)
Medical device (11345)
Medtech (11349)
Mergers & acquisitions (17129)
Metabolic disorders (594)
Neuroscience (1785)
NextGen: Class of 2025 (5272)
Non-profit (3319)
Northern California (1877)
Obesity (345)
Opinion (225)
Parkinson's disease (118)
Patents (147)
People (50610)
Phase I (18369)
Phase II (26651)
Phase III (21146)
Pipeline (668)
Postmarket research (2550)
Preclinical (7562)
Radiopharmaceuticals (226)
Rare diseases (319)
Real estate (5197)
Regulatory (21928)
Research institute (2182)
Resumes & cover letters (416)
Southern California (1604)
Startups (3235)
United States (16511)
Vaccines (680)
Weight loss (262)
Date
Today (102)
Last 7 days (603)
Last 30 days (2391)
Last 365 days (32884)
2025 (3284)
2024 (33289)
2023 (37222)
2022 (47704)
2021 (51385)
2020 (48652)
2019 (39202)
2018 (29904)
2017 (30548)
2016 (29175)
2015 (32677)
2014 (26562)
2013 (22192)
2012 (23752)
2011 (24429)
2010 (22346)
Location
Africa (759)
Arizona (166)
Asia (36988)
Australia (6053)
California (4252)
Canada (1394)
China (351)
Colorado (200)
Connecticut (223)
Europe (84366)
Florida (635)
Georgia (140)
Illinois (389)
Indiana (217)
Maryland (693)
Massachusetts (3321)
Michigan (161)
Minnesota (273)
New Jersey (1240)
New York (1192)
North Carolina (800)
Northern California (1877)
Ohio (138)
Pennsylvania (962)
South America (1133)
Southern California (1604)
Texas (608)
Utah (117)
Washington State (429)
600,602 Results for "veloxis pharmaceuticals a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bio NC
Veloxis Pharmaceuticals Selected to Present at the 2024 American Transplant Congress in Philadelphia
Veloxis Pharmaceuticals, Inc. is pleased to announce the presentation of VEL-101 research at the 2024 American Transplant Congress (ATC).
May 30, 2024
·
5 min read
Bio NC
Lyfebulb and Veloxis Pharmaceuticals Announce Finalists for 2022 Innovation Challenge in Organ Transplantation
Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, a fully integrated specialty pharmaceutical company, are pleased to announce 10 finalists for the 2022 “Transforming Organ Transplantation Through Innovation” Challenge.
September 19, 2022
·
4 min read
Press Releases
Acadia Pharmaceuticals Set to Join S&P SmallCap 600
December 31, 2024
·
1 min read
Press Releases
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
February 7, 2025
·
4 min read
Press Releases
Faraday Pharmaceuticals to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
February 5, 2025
·
1 min read
Bio NC
Biohope and C. Alan Foundation Named Winners of the 2022 Lyfebulb-Veloxis Innovation Challenge: Transforming Organ Transplantation
Lyfebulb and Veloxis Pharmaceuticals are excited to announce that Biohope was selected as the winner of the Innovation Award and C. Alan Foundation as the winner of the Impact Award at the 2022 Lyfebulb-Veloxis Innovation Challenge: Transforming Organ Transplantation.
October 17, 2022
·
4 min read
Press Releases
U.S. Pharmaceutical CDMO Market Size to Surpass 83.25 Bn by 2034
January 20, 2025
·
1 min read
Bio NC
Lyfebulb and Veloxis Pharmaceuticals Seek Applicants for the Global 2022 Innovation Challenge in Organ Transplantation
Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, an Asahi Kasei, fully integrated specialty pharmaceutical company, invite entrepreneurs to apply to their “Transforming Organ Transplantation Through Innovation” Challenge.
July 26, 2022
·
4 min read
FDA Tracker
2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval
Other notable greenlights this year include Bristol Myers Squibb’s Cobenfy, the first novel therapeutic for schizophrenia in 35 years, and Madrigal Pharmaceuticals’ Rezdiffra, the first-ever treatment for MASH.
December 24, 2024
·
223 min read
·
BioSpace Editorial Staff
Regulatory
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a third-party provider while releasing Amylyx’s investigational ALS therapy from a previous pause.
January 22, 2025
·
2 min read
·
Tristan Manalac
1 of 60,061
Next
